Selling Buzz: Nabriva Therapeutics plc [NBRV] Director BURGESS DANIEL D sells 11,341 shares of the company

Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Nabriva Therapeutics plc shares valued at $2,156 were sold by BURGESS DANIEL D on Aug 02. At $0.19 per share, BURGESS DANIEL D sold 11,341 shares. The insider’s holdings dropped to 10,384 shares worth approximately $1869.12 following the completion of this transaction.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored


Also, Broom Colin MD sold 5,339 shares, netting a total of over 1,015 in proceeds. Following the sale of shares at $0.19 each, the insider now holds 36,523 shares.

Before that, Webster Stephen W had sold 7,826 shares from its account. In a trade valued at $1,487, the Director traded Nabriva Therapeutics plc shares for $0.19 each. Upon closing the transaction, the insider’s holdings decreased to 7,826 shares, worth approximately $2060.46.

As published in a research note from Wedbush on March 19, 2020, Nabriva Therapeutics plc [NBRV] has been rated down from an Outperform to a Neutral. Analysts at Gabelli & Co upgraded the stock from ‘”a Sell”‘ to ‘”a Hold”‘ outlook in a report released in early May. As of May 02, 2019, H.C. Wainwright has reiterated its “Buy” rating for NBRV.

Analyzing NBRV’s Price Performance

On Thursday, Nabriva Therapeutics plc [NASDAQ: NBRV] plunged -8.07% to $0.18. The stock’s lowest price that day was $0.1776, but it reached a high of $0.194 in the same session. During the last five days, there has been a surge of approximately 2.32%. Over the course of the year, Nabriva Therapeutics plc shares have dropped approximately -69.76%. Shares of the company reached a 52-week high of $0.7106 on 01/04/22 and a 52-week low of $0.1559 on 07/26/22. A 50-day SMA is recorded $0.1928, while a 200-day SMA reached $0.4884. Nevertheless, trading volume fell to 1.03 million shares from 0.58 million shares the previous day.

Support And Resistance Levels for Nabriva Therapeutics plc (NBRV)

According to the 24-hour chart, there is a support level at 0.1745, which, if violated, would cause prices to drop to 0.1678. In the upper region, resistance lies at 0.1909. The next price resistance is at 0.2006. RSI (Relative Strength Index) is 46.97 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.0077, which suggests the price will decrease in the coming days. Percent R is at 61.47%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.

Is Nabriva Therapeutics plc subject to short interest?

Stocks of Nabriva Therapeutics plc saw a sharp rise in short interest on Jul 14, 2022 jumping by 41430.0 shares to 0.57 million. Data from Yahoo Finance shows that the short interest on Jun 14, 2022 was 0.53 million shares. A jump of 7.25% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 0.59 of the overall float, the days-to-cover ratio (short ratio) jumped to 0.59.

Which companies own the most shares of Nabriva Therapeutics plc (NBRV)?

According to Fidelity Management & Research Co filings, the company currently owns 1,343,459 shares, which is about 2.13% of the total NBRV shares outstanding. The investor’s shares have plunged by 0 from its previous 13-F filing of 1343459.0 shares. With the completion of the sale transaction, Medical Strategy GmbH’s stake is now worth $85,357. Renaissance Technologies LLC reduced a -16.45% interest valued at $71671.0 while ACATIS Investment Kapitalverwaltu sold a -1,271 stake. A total of 0 shares of Nabriva Therapeutics plc were sold by Aisling Capital Management LP during the quarter, and 0 were sold by Apo Asset Management GmbH. In its current portfolio, Morgan Stanley & Co. LLC holds 117,138 shares valued at $21319.0.

In terms of Nabriva Therapeutics plc share price expectations, FactSet research, analysts set an average price target of $2.00 in the next 12 months, up nearly 900.0% from the previous closing price of $0.20. Analysts anticipate Nabriva Therapeutics plc stock to reach $2.00 by 2022, with the lowest price target being $2.00. In spite of this, 1 analysts ranked Nabriva Therapeutics plc stock as a Buy at the end of 2022. On March 21, 2018, BofA/Merrill assigned a price target of “a Buy” to the stock and initiated coverage with a $10.

LEAVE A REPLY

Please enter your comment!
Please enter your name here